Dacomitinib (trade name Vizimpro) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR. Reference standards of Dacomitinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Dacomitinib
Catalogue No.:PA 04 2190000
CAS :
Molecular Formula : C24H25ClFN5O2
Molecular Weight : 469.95
1-(4-((3-Chloro-4-fluorocyclohexyl)amino)-7-methoxyquinazolin-6-yl)-5-hydroxypyrrolidin-2-one
Catalogue No.:PA 04 2191000
Molecular Formula : C19H16ClFN4O3
Molecular Weight : 402.81
Dacomitinib Desmethyl Impurity
Catalogue No.:PA 04 2191001
Molecular Formula : C23H23ClFN5O2
Molecular Weight : 455.92
Dacomitinib Z-Isomer
Catalogue No.:PA 04 2191002
(E)-N-(4-((3-Chloro-4-fluorophenyl)(nitroso)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide
Catalogue No.:PA 04 2191003
Molecular Formula : C24H24ClFN6O3
Molecular Weight : 498.94
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
